You are here

Analysis Tools for Detection and Diagnosis of Biological Threats

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: DAMD17-04-C-0095
Agency Tracking Number: C041-113-0104
Amount: $413,933.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD04-113
Solicitation Number: 2004.1
Timeline
Solicitation Year: 2004
Award Year: 2005
Award Start Date (Proposal Award Date): 2005-05-15
Award End Date (Contract End Date): 2007-06-15
Small Business Information
4700 Falls of Neuse, Suite 350
Raleigh, NC 27609
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Hong Dang
 Senior Bioinformatician
 (919) 954-0033
 hdang@alpha-gamma.com
Business Contact
 Reese Howle
Title: President
Phone: (919) 954-0033
Email: rhowle@alpha-gamma.com
Research Institution
N/A
Abstract

DNA microarray technology, in combination with statistical and predictive modeling tools, could be used to evaluate thousands of genes against distinct gene expression patterns induced by chemical/biological agents to provide early identification and speed therapeutic intervention. The overall objective of this Phase II effort is to leverage existing public domain resources and commercial tools to provide the Army with a comprehensive data management system with integrated statistical and pattern recognition tools capable of: 1) Identifying agent specific gene profile biomarker signatures; 2) Teasing out exogenous factors such as ingested food, stressors, etc.; 3) Discriminating naturally occurring diseases from weaponized biological agents; and 4) Linking gene expression responses to physiological responses. Similar needs for a data management system with statistical and visualization tools exists in the private sector, specifically basic research and the pharmaceutical industry. The secondary objective of Phase II is to develop a product that meets private sector needs as well as those of the Army. At the conclusion of Phase II, Alpha-Gamma will have a product (bioCAT) ready for commercialization in the private sector.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government